Login to Your Account



Cell Therapeutics' Pacritinib Phase III Program Takes Off

By Catherine Shaffer
Staff Writer

Thursday, January 10, 2013
Cell Therapeutics Inc., of Seattle, began a much-anticipated Phase III trial for its JAK2 inhibitor, pacritinib, in myelofibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription